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During typesetting of the aforementioned
article, a number of erroneous commas were
inadvertently introduced into the quantities
cited. Furthermore, the authors noted that the
description of Fig. 2 was incorrect in the results
section. As such, the following corrections
should be highlighted:
In the Results section of the Abstract, the
following sentence is incorrect ‘We identified
4,85,895 orthopedic surgery patients with
1,74,805 (36%) who had received IV
acetaminophen.’ and should read ‘We
identified 485,895 orthopedic surgery patients
with 174,805 (36%) who had received IV
acetaminophen’.
In the Results section, the following sentence
is incorrect ‘We identified 4,85,895 orthopedic
surgery patients who were eligible for our study
of which 1,74,805 (36%) had been managed
with IV acetaminophen and opioids and
3,11,090 (64%) had been managed with IV
opioids alone.’ and should read as follows ‘We
identified 485,895 orthopedic surgery patients
who were eligible for our study of which
174,805 (36%) had been managed with IV
acetaminophen and opioids and 311,090
(64%) had been managed with IV opioids
alone’.
Also in the Results section, the following
sentence is incorrect ‘Subgroup analyses by
surgery type revealed that LOS was
consistently lower across all surgery groups,
though only the fracture and other subgroups
were statistically significantly lower. These
subgroup analyses also showed that while
costs were estimated to be lower for most
groups, they were slightly higher for total knee
replacements and other surgeries, none of
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Table 1 Demographic characteristics of orthopedic surgery patients, comparing IV acetaminophen (Oﬁrmev) recipients to
IV opioid monotherapy recipients
Characteristic IV opioids (n5 311,090) IV acetaminophen (n5 174,805)
Age (years), mean (SD) 64.3 (15.6) 63.6 (14.0)
Female, n (%) 179,779 (57.8) 102,864 (58.8)
Race, n (%)
White 238,421 (76.6) 140,748 (80.5)
Black 24,876 (8.0) 14,591 (8.4)
Hispanic 47,600 (15.3) 19,362 (11.1)
Unknown 193 (0.1) 104 (0.1)
APR-DRG severity of illness, n (%)
Minor 136,264 (43.8) 80,801 (46.2)
Moderate 130,231 (41.9) 77,862 (44.5)
Severe 36,973 (11.9) 14,462 (8.3)
Extreme 7622 (2.5) 1680 (1.0)
APR-DRG risk of mortality, n (%)
Minor 217,279 (69.8) 137,283 (78.5)
Moderate 63,080 (20.3) 28,648 (16.4)
Severe 24,654 (7.9) 7454 (4.3)
Extreme 6077 (1.9) 1420 (0.8)
Elective surgery, n (%) 210,663 (67.7) 136,318 (78.0)
Hospital region, n (%)
Midwest 60,685 (19.5) 27,639 (15.8)
Northeast 70,154 (22.6) 28,530 (16.3)
South 132,013 (42.4) 104,113 (59.6)
West 48,238 (15.5) 14,523 (8.3)
Surgery type, n (%)
Total knee replacement 66,725 (21.4) 64,399 (36.8)
Total hip replacement 40,140 (12.9) 33,541 (19.2)
Knee revision 5187 (1.7) 4869 (2.8)
Hip revision or partial replacement 26,672 (8.6) 9671 (5.5)
Fracture 64,395 (20.7) 17,928 (10.3)
Othera 107,971 (34.7) 44,397 (25.4)
APR-DRG all patient reﬁned-diagnosis related group, IV intravenous, SD standard deviation
a Shoulder and spine
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which were statistically significantly different.
Opioid dose was also lower for all groups
(non-significant with the exception of other)
except MED was slightly higher for knee
revisions (1.1 mg, P = 0.8; Fig. 2).’ And should
read as follows ‘Subgroup analyses by surgery
type revealed that LOS was statistically
significantly lower for all groups with the
exception of knee revision. These subgroup
analyses also showed that while costs were
estimated to be lower for most groups, they
were slightly higher for total knee replacements
and other surgeries, neither of which were
statistically significantly higher. Opioid dose
was also lower for all groups except MED was
slightly higher for knee revisions (1.1 mg, P =
0.8; Fig. 2)’.
A number of errors were noted in Table 1.
Table 1 should appear as above.
Furthermore, errors were noted in the field
headings of Table 2. Table 2 should appear as
above.
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Difference (95% CI) P value
Length of stay (days), mean
(SD)
3.9 (3.9) 3.2 (2.6) -0.66 (-0.68 to -0.64) \0.0001
Hospitalization cost ($), mean
(SD)
19,927.6 (19,578.8) 19,024.9 (13,113.7) -902.7 (-1005.4 to -800.0) \0.0001
Morphine equivalent dose
(mg), mean (SD)
43.8 (53.4) 46.9 (44.5) 3.1 (2.8 to 3.4) \0.0001
Opioid-related AEs, ORa (95% CI)
Urinary tract infection 0.596 (0.56 to 0.63) \0.0001
Respiratory depression 0.518 (0.50 to 0.54) \0.0001
Surgery site infection 0.754 (0.71 to 0.80) \0.0001
Bowel obstruction 1.013 (0.99 to 1.04) 0.4
Nausea/vomiting 1.208 (1.16 to 1.26) \0.0001
AE adverse event, CI conﬁdence interval, OR odds ratio, IV intravenous, SD standard deviation
a IV opioid monotherapy is the reference group
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